Target-oriented synthesis of antiparasitic 2-hetaryl substituted quinolines based on imino Diels-Alder reactions

Letters in Drug Design and Discovery

Volumn 4, Issue 4, 2007, Pages 293-296

  Kouznetsov, Vladimir V ^a   Méndez, Leonor Y Vargas ^a   Leal, Sandra Milena ^a   Cruz, Uriel Mora ^a   Coronado, Carlos Andrés ^a   Gómez, Carlos M Meléndez ^a   Bohórquez, Arnold R Romero ^a   Rivero, Patricia Escobar ^a  

^a UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

Author keywords

2 hetarylquinolines; Antiparasitic activities; Drug discovery; Leishmania chagasi; Target oriented synthesis; Trypanosoma cruzi

Indexed keywords

2 (BETA PYRIDINYL)QUINOLINE; 2 PHENYLQUINOLINE; 4 METHYL 2 ISOPROPYL (4 PYRIDINYL)QUINOLINE; 4 METHYL 8 ISOPROPYL 2 (3 PYRIDINYL)QUINOLINE; AMPHOTERICIN B; ANTIPARASITIC AGENT; NIFURTIMOX; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIELS ALDER REACTION; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EPIMASTIGOTE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEISHMANIA CHAGASI; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

EID: 34248172806     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018007784620031     Document Type: Article

References (18)

1. TDR Homepage. 2006. http://www.who.int/tdr
2. Croft, S.L.; Barrett, M.P.; Urbina, J.A. Trends Parasitol., 2005, 21, 508.
3. (a) Franck, X.; Fournet, A.; Prina, E.; Mahieux, R.; Hocquemiller, R.; Figadère, B. Bioorg. Med. Chem. Lett., 2004, 14, 3635;
4. (b) Fakhfakh, M.A.; Fournet, A.; Prina, E.; Mouscadet, J.F.; Franck, X.; Hocquemiller, R.; Figadère, B. Bioorg. Med. Chem., 2003, 11, 5013;
5. (c) Nakayama, H.; Loiseau, P.M.; Bories, C.; Torres de Ortiz, S.; Schinini, A.; Serna, E.; Rojas de Arias, A.; Fakhfakh, M.A.; Franck, J.; Figadère, B.; Hocquemiller, R.; Fournet, A. Antimicrob. Agents. Chemother., 2005, 49, 4950;
6. (d) Dietze, R.S.F.; Carvalho, L.C.; Valli, J.; Berman, T.; Brewer, W.; Milhous, J.; Sanchez, B.; Schuster, B.; Grogl, M. Am. J. Trop. Med. Hyg., 2001, 65, 685;
7. (e) Tempone, A.G.; Melo Pompeu da Silva, A.C.; Brandt, C.A.; Scalzaretto Martinez, F.; Treiger Borborema, S.E.; Baratada da Silveira, M.A.; Andrade Jr, H.F. Antimicrob. Agents. Chemother., 2005, 49, 1076;
8. (f) Sahu, N.P.; Pal, C.; Mandal N.P.; Banerjee, S.; Raha, M.; Kundu, A.P.; Basu, A.; Ghosh, M.; Roy, K.; Bandyopadhyay, S. Bioorg. Med. Chem. Lett., 2002, 10, 1687.
9. (a) Kouznetsov, V.V.; Vargas Méndez, L.Y.; Tibaduiza, B.; Ochoa, C.; Montero Pereira, D.; Nogal Ruiz, J.J.; Portillo, C.F; Gómez, A.B.; Bahsas, A.; Amaro-Luis, J. Archiv der Pharmazie, 2004, 337, 127;
10. (b) Kouznetsov, V.; Rodríguez, W.; Stashenko, E.; Ochoa, C.; Vega, C.; Rolón, M.; Montero Pereira, D.; Escario, J. A.; Gómez Barrio, A. J. Heterocycl. Chem., 2004, 41, 995;
11. (c) Urbina, J.M.G.; Cortés, J.C.; Palma, A.; López, S.N.; Zacchino, S.A.; Enriz, D.R.; Ribas, J.C.; Kouznetsov, V. Bioorg. Med. Chem., 2000, 8, 691;
12. (d) Vargas, M.L.Y.; Castelli, M.V.; Kouznetsov, V.V.; Urbina, G.J.M.; López, S.N.; Sortino, M.; Enriz, R.D.; Ribas, J.C.; Zacchino S.A. Bioorg. Med. Chem., 2003, 11, 1531;
13. (e) Muscia, G.C.; Bollini, M.; Carnevale, J.P.; Bruno, A.M.; Asís, S.E. Tetrahedron Lett., 2006, 47, 8811.
14. Layer, R.W. Chem. Rev., 1963, 63, 489.
15. Kouznetsov, V.V.; Bohórquez Romero, A.R.; Astudillo Saavedra, L.; Fierro Medina, R. Mol. Divers. 2006, 10, 29.
16. Kouznetsov, V.V.; Meléndez Gómez, C.M.; Urbina González J.M., Stashenko E.E., Bahsas A., Amaro-Luis J. J. Heterocycl. Chem., 2006, 43, in press.
17. For Leishmania assays, see: Escobar P.; Matu S.; Marques C.; Croft S.L. Acta Trop., 2002, 81, 151.
18. 2-95% air mixture at 37°C. After 24 h infected cultures were incubated with the compounds in a 3-fold dilution series in triplicate at each concentration for 72 h. Drug activity was determined from the % of infected cells in treated and untreated cultures in methanol fixed and Giemsa stained preparations. For mammalian cell toxicity: Vero cells or transformed THP-1 cells were incubated with the compound as above and the cell toxicity was analysed followed the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction assay described by Mosmann, T. J. Immunol. Methods, 1983, 65, 55.